Initial investigation of efficacy and safety of a new dipeptidyl peptidase-4 inhibitor, gosogliptin, for type 2 diabetes in Russia
Current treatment strategies for type 2 diabetes mellitus (T2DM) are based on using safe and effective hypoglycaemic agents for preventing diabetic vascular complications and reducing the risks associated with weight gain and hypoglycaemia. These goals may be achieved using new agents with a fundame...
Saved in:
| Main Authors: | Lyudmila Viktorovna Nedosugova, Nina Alexandrovna Petunina, Karina Oganesovna Galstyan |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Endocrinology Research Centre
2014-12-01
|
| Series: | Сахарный диабет |
| Subjects: | |
| Online Access: | https://www.dia-endojournals.ru/jour/article/view/6740 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
First Russian DPP-4 inhibitor Gosogliptin comparing to Vildagliptin in type 2 diabetes mellitus patients
by: Karina Oganesovna Galstyan, et al.
Published: (2016-01-01) -
Practical Applications of Russian DPP4 Inhibitor Gosogliptin in “Palitra” Large-Scale Observational Study
by: M. V. Shestakova, et al.
Published: (2024-09-01) -
UNEXPECTED ADVERSE REACTIONS OF THE DRUGS OF THE GROUP OF INHIBITORS OF DIPEPTIDYL PEPTIDASE-4
by: T. V. Romanova, et al.
Published: (2018-06-01) -
Dipeptidyl peptidase-4 inhibitors: their role in the management of type 2 diabetes
by: Gail Mkele
Published: (2013-12-01) -
Possible applications of gliptins (dipeptidyl peptidase-4 inhibitors) in patients with type 2 diabetes mellitus on the various modes of insulin therapy
by: Gagik Radikovich Galstyan, et al.
Published: (2015-12-01)